Fulphila (Pegfilgrastim)
Neutropenia
ApprovedCommercial
Key Facts
About Biocon
Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has evolved from a garage startup into Asia's premier biotechnology enterprise with a focus on affordable healthcare solutions. The company operates through three key subsidiaries: Biocon Biologics (biosimilars), Biocon Pharma (generics), and Syngene (research services), serving patients in over 120 countries. Biocon has established itself as a pioneer in insulin manufacturing and biosimilar development, with multiple products approved by stringent regulatory authorities including FDA and EMA.
View full company profileTherapeutic Areas
Other Neutropenia Drugs
| Drug | Company | Phase |
|---|---|---|
| Pegfilgrastim Biosimilar | Dr. Reddy's Laboratories | Approved |